We are monitoring the impact of COVID-19 on APAC Uterine Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1413
Share on
Share on

Asia Pacific Uterine Cancer Therapeutics Market Research Report – Segmented By Type, Therapy, Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends, Forecast (2019 - 2024)

Pulished: February, 2020
ID: 1413
Pages: 135

APAC Uterine Cancer Therapeutics Market Size & Growth (2019 – 2024)

The size of the Uterine Cancer Therapeutics Market in the Asia Pacific is expected to reach $4.14 Billion by 2024 from $3 Billion in 2019, growing at a CAGR of 6.67% during the forecast period 2019 - 2024.

Uterine cancer is one of the most commonly prevailing malignant tumors that start in the cells of the uterus and spreads to other parts of the body. Uterine cancer is mainly of two types such as uterine sarcoma and endometrial carcinoma. Till now more numbers of therapies have been evolved to manage uterine cancer types include surgery, chemotherapy, radiation therapy, immunotherapy, and hormone therapy.

Increasing focus of government to provide early detection programs for uterine cancer, rising provision of optimal therapeutic strategies to treat uterine cancer, growing economy, and increasing advancements in the cancer screening & treatment methods are driving the growth of Asia-Pacific Uterine Cancer Therapeutics Market.

However, high cost of the treatment solutions, limited access for advanced cancer therapies in certain developing areas are expected to restrain the growth of Uterine Cancer Therapeutics Market.

This research report has been segmented & sub-segmented into the following categories:

  • By Type: Uterine Sarcoma, Endometrial Carcinoma (Adenocarcinoma, Carcinosarcoma, Squamous Cell Carcinoma, Others)
  • By Therapy: Surgery, Chemotherapy, Radiation Therapy, Immunotherapy and Hormone Therapy
  • By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC

On the basis of type, the Endometrial Carcinoma segment is expected to hold the major market share in the North America Uterine Cancer Therapeutics market.

Notable companies in the APAC Uterine Cancer Therapeutics market profiled in this report are Abbott Laboratories, Ariad Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis AG, Sanofi, Siemens Healthcare GmbH and Takeda Pharmaceutical Company Ltd.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Type                        

                                5.1.1 Endometrial Carcinoma     

                                                5.1.2.1 Adenocarcinoma

                                                5.1.2.2 Carcinosarcoma

                                                5.1.2.3 Squamous cell carcinoma

                                                5.1.2.4 Others

                                5.1.2 Uterine Sarcoma  

                5.2 By Therapy                 

                                5.2.1 Surgery    

                                5.2.2 Chemotherapy     

                                5.2.3 Radiation Therapy

                                5.2.4 Immunotherapy   

                                5.2.5 Hormone Therapy

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 China                            

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea               

                6.6 Australia                      

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Abbott Laboratories (U.S.)                   

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Ariad Pharmaceuticals, Inc. (U.S.)                     

                9.3 Becton, Dickinson and Company (U.S.)                           

                9.4 F. Hoffmann-La Roche AG (Switzerland)                        

                9.5 GlaxoSmithKline Plc (U.K.)                   

                9.6 Merck & Co., Inc. (U.S.)                         

                9.7 Novartis AG (Switzerland)                    

                9.8 Sanofi (France)                         

                9.9 Siemens Healthcare GmbH (Germany)                           

                9.10 Takeda Pharmaceutical Company Ltd. (Japan)                          

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Market Outlook & Investment Opportunities                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Uterine Cancer Therapeutics Market By Region, From 2019-2024 ( USD Billion )
  2. Asia-Pacific Uterine Cancer Therapeutics Market By Type, From 2019-2024 ( USD Billion )
  3. Asia-Pacific Endometrial Carcinoma Market By Region, From 2019-2024 ( USD Billion )
  4. Asia-Pacific Uterine Sarcoma Market By Region, From 2019-2024 ( USD Billion )
  5. Asia-Pacific Uterine Cancer Therapeutics Market By Therapy, From 2019-2024 ( USD Billion )
  6. Asia-Pacific Uterine Cancer Surgery Market By Region, From 2019-2024 ( USD Billion )
  7. Asia-Pacific Uterine Cancer Chemotherapy Market By Region, From 2019-2024 ( USD Billion )
  8. Asia-Pacific Uterine Cancer Immunotherapy Market By Region, From 2019-2024 ( USD Billion )
  9. Asia-Pacific Uterine Cancer Radiation Therapy Market By Region, From 2019-2024 ( USD Billion )
  10. Asia-Pacific Uterine Cancer Hormone Therapy Market By Region, From 2019-2024 ( USD Billion )
  11. China Uterine Cancer Therapeutics Market By Type, From 2019-2024 ( USD Billion )
  12. China Uterine Cancer Therapeutics Market By Therapy, From 2019-2024 ( USD Billion )
  13. India Uterine Cancer Therapeutics Market By Type, From 2019-2024 ( USD Billion )
  14. India Uterine Cancer Therapeutics Market By Therapy, From 2019-2024 ( USD Billion )
  15. Japan Uterine Cancer Therapeutics Market By Type, From 2019-2024 ( USD Billion )
  16. Japan Uterine Cancer Therapeutics Market By Therapy, From 2019-2024 ( USD Billion )
  17. South Korea Uterine Cancer Therapeutics Market By Type, From 2019-2024 ( USD Billion )
  18. South Korea Uterine Cancer Therapeutics Market By Therapy, From 2019-2024 ( USD Billion )
  19. Australia Uterine Cancer Therapeutics Market By Type, From 2019-2024 ( USD Billion )
  20. Australia Uterine Cancer Therapeutics Market By Therapy, From 2019-2024 ( USD Billion )
  21. Asia-Pacific Endometrial Carcinoma Market By Type, From 2019-2024 ( USD Billion )
  22. Asia-Pacific Adenocarcinoma Market By Region, From 2019-2024 ( USD Billion )
  23. Asia-Pacific Carcinosarcoma Market By Region, From 2019-2024 ( USD Billion )
  24. Asia-Pacific Squamous cell carcinoma Market By Region, From 2019-2024 ( USD Billion )
  25. Asia-Pacific Other Endometrial Carcinoma Market By Region, From 2019-2024 ( USD Billion )
  26. China Endometrial Carcinoma Market By Type, From 2019-2024 ( USD Billion )
  27. India Endometrial Carcinoma Market By Type, From 2019-2024 ( USD Billion )
  28. Japan Endometrial Carcinoma Market By Type, From 2019-2024 ( USD Billion )
  29. South Korea Endometrial Carcinoma Market By Type, From 2019-2024 ( USD Billion )
  30. Australia Endometrial Carcinoma Market By Type, From 2019-2024 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample